Welcome to the Third 2019 Issue of The CLL Society Tribune
As you explore this Q3 2019 Issue of the CLL Society Tribune, you will fall into step with other CLL patients who are walking in your shoes as they write about their large and small worries, offer poetry, ask questions, and receive answers from our CLL doctors, laboratory scientist, pharmacist, and end of life doctor who mobilize their considerable depth of knowledge and experience to answer our community’s questions.
Keep in touch. Stay strong. We are all in this together.
If you or a loved one has been helped by the CLL Society, please consider making a donation.
Best of health!
Patricia Koffman, Executive Director
P.O. Box 1390
Claremont, CA 91711
By Bob Barton – Patient
This is a continuation of my previous two articles that are chronicles of my fight with CLL. In continuing the series, I hope to shed light on using ibrutinib to manage CLL for those patients who are nearing the end of their “watch and wait” status and need to decide on a therapy. … Read more
During July through September 2019, the CLL Society conducted a poll among readers of The CLL Society Tribune. … See the results!
CLL Tribune is accepting all forms of storytelling, including articles, poems, drawings, or other creative mediums. Contribute today! Email firstname.lastname@example.org with your interest!
There are many prognostic and predictive tests that can be ordered at different times on our CLL journey. Here are my own thoughts on this frequently asked question. … Read more
The landscape of CLL is changing fast. Novel therapies and combinations are being studied and approved at a significant pace. Venetoclax is a very potent anti-CLL agent that’s approved in the relapsed setting both as a single-agent and in combination with rituximab … Read more
ASH 2018: Dr. Nitin Jain on combining Ibrutinib with Fludarabine, Cyclophosphamide and Obinutuzumab for IGVH mutated CLL patients.
By Brian Koffman, MD
Could we have the best of both worlds- the fast kill and fixed dose of chemo and the power of a targeted agent? I had the opportunity to interview Dr. Jain at the annual meeting of the American Society of Hematology in San Diego in Dec. 2018, where he describes his early research results with just such a cocktail. … Watch The Interview
By Richard Furman, MD
Dr. Richard Furman of Weill-Cornell Medical College answers readers’ questions submitted to the CLL Society…Read more
Thomas E Henry III, MBA, RPh, CPh from Burlington Consulting Associates answers readers’ pharmacy questions submitted to the CLL Society…Read more
Susan J. Leclair from University of Massachusetts Dartmouth answers readers’ lab scientist questions submitted to the CLL Society…Read more
Dr. Ratner at the Minneapolis VA Medical Center answers readers’ hospice/palliative care questions submitted to the CLL Society… Read more
We’d like to thank the supporters of The CLL Tribune:
- Genentech/Biogen Idec
- Sunesis Pharmaceuticals
- TG Therapeutics
The CLL Society does not provide medical advice or endorsements. Unless explicitly stated otherwise, all content in the CLL Tribune is the opinion or information of its author, not the CLL Society. This newsletter is for reference and educational purposes only and is not a substitute for medical advice. We do not guarantee the accuracy of any of the materials. Always contact your own doctor or other professional healthcare provider if you have any questions concerning your or your family’s health. Everyone’s circumstances are different.